Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Basal Cell 5Medulloblastoma 4Recurrence 3Basal Cell Nevus Syndrome 2Thrombocytosis 1Thrombocythemia, Essential 1Stomach Neoplasms 1Skin Neoplasms 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroblastoma 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hepatoblastoma 1Hemorrhagic Disorders 1Hematologic Neoplasms 1Hematologic Diseases 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1

Interventions

ruxolitinib 21Azacitidine 5ponatinib 4parsaclisib 4nilotinib 4itacitinib 4anagrelide 3Phlebotomy 3Imatinib Mesylate 3INCB039110 3Aspirin 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2pemigatinib 2luspatercept 2imetelstat 2givinostat hydrochloride 2givinostat 2fedratinib 2asciminib 2INCB057643 2Gemcitabine 2GRN163L peptide 2spartalizumab 1sonidegib 1selinexor 1sabatolimab 1rucaparib 1pembrolizumab 1navitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Myeloproliferative Disorders × sonidegib × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡